

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-47 (canceled).

Claim 48. (currently amended) A method for inducing a cellular immune response in a patient against a tumor that expresses carcinoembryonic antigen (CEA), said method comprising:

administering an effective immunostimulatory amount of transfected T cells to a patient;

and

subsequently administering at least one cytokine to said patient;

wherein said transfected T cells are produced by obtaining T cells from the patient and

transfecting said T cells with an expression vector to obtain said transfected T cells;

wherein said expression vector comprises a DNA molecule encoding either a chimeric immunoglobulin/T cell receptor or a chimeric immunoglobulin/CD3 protein, and wherein

said immunoglobulin-encoding portion of said DNA molecule encodes the variable

regions of a Class III anti-CEA antibody, wherein the Class III anti-CEA antibody is

MN-14 or humanized MN-14, and further wherein the variable regions of the α and β

polypeptide chains of said T cell receptor are replaced by said variable regions of the

antibody.

Claim 49. (previously presented) The method of claim 48, wherein the cytokine is selected from the group consisting of interferon- γ and interleukin-2.

Claim 50. (canceled).

Claim 51. (previously presented) The method of claim 49, wherein said transfected T cells are stimulated *ex vivo* to obtain an increased mass of cells.

Claim 52. (Currently amended) A method for inducing a cellular immune response in a patient against a tumor that expresses carcinoembryonic antigen (CEA), said method comprising:

administering an effective immunostimulatory amount of transfected T cells to a patient;

and

subsequently administering at least one cytokine to said patient;

wherein said T cells are produced by obtaining T cells from the patient and transfecting said T cells with an expression vector to obtain said transfected T cells;

wherein said expression vector comprises a DNA molecule encoding either a chimeric immunoglobulin/T cell receptor or a chimeric immunoglobulin/CD3 protein, and wherein said immunoglobulin-encoding portion of said DNA molecule encodes the variable regions of an anti-idiotypic antibody that recognizes a Class III anti-CEA antibody, wherein the anti-idiotypic antibody is WI2, and further wherein the variable regions of the α and β polypeptide chains of said T cell receptor are replaced by said variable regions of the antibody.

Claim 53. (previously presented) The method of claim 52, wherein the cytokine is selected from the group consisting of interferon- γ and interleukin-2.

Claim 54. (canceled).

Claim 55. (previously presented) The method of claim 52, wherein said transfected T cells are stimulated *ex vivo* to obtain an increased mass of cells.

Claims 56 - 59 (canceled).